Daniel Jafferji
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Internal Medicine top 10%
- Venous Thromboembolism Diagnosis and Management
Papers in
-
- COVID-19 Clinical Research Studies 5
-
- Ultrasound in Clinical Applications 2
- Journals
- The Lancet (5 papers)Intensive Care Medicine (2 papers)British Journal of Anaesthesia (2 papers)
- Partner nations
- United KingdomVietnamNepal
In The Last Decade
Daniel Jafferji
7 papers receiving 1.2k citations
Daniel Jafferji's Hit Papers
Peers
Comparison fields: 5 of 75
- Infectious Diseases 949
- Internal Medicine 27
- Hematology 36
- Statistics and Probability 32
- Oncology 53
Countries citing papers authored by Daniel Jafferji
This map shows the geographic impact of Daniel Jafferji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Jafferji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Jafferji more than expected).
Fields of papers citing papers by Daniel Jafferji
This network shows the impact of papers produced by Daniel Jafferji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Jafferji. The network helps show where Daniel Jafferji may publish in the future.
Co-authors
The 2 scholars most cited alongside Daniel Jafferji, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 2 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 3 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 4 | 2021 | 213 | |
| 5 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 6 | 2019 | 11 | |
| 7 | 2024 | 11 | |
| 8 | 2024 | 0 | |
| 9 | 2025 | 0 |
About Daniel Jafferji
Daniel Jafferji is a scholar working on Infectious Diseases, Critical Care and Intensive Care Medicine, Anesthesiology and Pain Medicine, Family Practice and Nuclear Energy and Engineering, having authored 9 papers that have together received 1.2k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (5 papers), Ultrasound in Clinical Applications (2 papers), Airway Management and Intubation Techniques (2 papers) and Clinical Reasoning and Diagnostic Skills (1 paper). The work is most often cited by research in Infectious Diseases (949 citations), Internal Medicine (27 citations), Hematology (36 citations), Statistics and Probability (32 citations) and Oncology (53 citations). Daniel Jafferji has collaborated with scholars based in United Kingdom, Vietnam and Nepal. Frequent co-authors include Nicholas Levy and Peter Young. Their work appears in journals such as The Lancet, Intensive Care Medicine and British Journal of Anaesthesia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.